{
    "clinical_study": {
        "@rank": "68687", 
        "arm_group": {
            "arm_group_label": "Study Arm", 
            "arm_group_type": "Experimental", 
            "description": "Eligible patients will begin with a 14-day lead-in period with afatinib alone. This will be followed immediately by 2 cycles of induction chemotherapy (IC) with carboplatin AUC 6 IV Day 1, paclitaxel 175mg/m2 IV Day 1, and oral afatinib as a continuous daily dosing. Each cycle is repeated every 21 days. After completion of 2 cycles of IC, patients will be assessed for response by CT/MRI and clinical exam. After the induction, all patients will receive Intensity Modulated Radiation Therapy (IMRT) with weekly cisplatin 40mg/m2 IV. Chemoradiotherapy (CRT) will begin 2-3 weeks after the completion of the second cycle of IC. The patients will be evaluated with a MRI or CT, and FDG PET approximately 12 weeks after completion of CRT."
        }, 
        "brief_summary": {
            "textblock": "Trial Objectives:\n\n      The objective is to investigate the efficacy and safety of afatinib with induction\n      chemotherapy in primary unresected patients with locally advanced, HPV-negative, stage III\n      or IVa/b HNSCC including oral cavity, oropharynx, hypopharynx, or larynx.\n\n      Primary Objective Phase I The primary objective of the phase I portion of the trial is to\n      determine the maximum tolerated dose (MTD) or the recommended phase II dose of daily oral\n      afatinib that is safe in combination with carboplatin AUC 6 and paclitaxel 175mg/m2 q 21\n      days as an induction regimen.\n\n      Primary Objective Phase 2 The primary objective of the phase 2 portion of the trial is to\n      estimate the objective tumor response rate and toxicity with induction therapy in patients\n      treated on the afatinib dose determined in Phase I.\n\n      Secondary Objectives The secondary objective of phase II is to estimate: 1) the overall\n      response to entire treatment after completion of CRT, 2) progression-free survival (PFS)\n      rate at 2 years, and 3) overall survival (OS) at 2 years."
        }, 
        "brief_title": "A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Squamous Cell Carcinoma of the Head and Neck", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase I/phase II prospective multicenter trial to investigate the efficacy and\n      safety of afatinib with induction chemotherapy in primary unresected patients with\n      HPV-negative locally advanced SCC stage III or IVa/b of oral cavity, oropharynx,\n      hypopharynx, or larynx. The primary endpoint is overall response rate after the completion\n      of induction chemotherapy.\n\n      Eligible patients will begin with a 14 day lead-in period with afatinib alone. This will be\n      followed immediately by 2 cycles of induction chemotherapy with carboplatin AUC 6 IV,\n      paclitaxel 175mg/m2 day 1, and afatinib as a continuous daily dosing. Each cycle is repeated\n      every 21 days. All patients will receive concurrent chemoradiotherapy beginning 2-3 weeks\n      after the completion of the second cycle of induction chemotherapy (Refer to Study Schema in\n      page 8 of the protocol).\n\n      During the period of induction chemotherapy, a complete history and physical (including\n      weight) and tumor assessment by physical examination on Day 1 of each cycle will be\n      performed and documented. Complete blood count with differential and a comprehensive\n      metabolic profile will be performed weekly. After completion of induction chemotherapy,\n      reassessment with blood work, physical exam, CT/MRI of neck and nasopharyngolaryngoscopy\n      will be performed. After the completion of CRT, the patient will have a MRI, CT, or FDG PET\n      approximately 12 weeks after CRT. Follow-up will be standard of care from this point\n      onwards.\n\n      Physical exam, blood work and AE assessments will also be frequently performed during entire\n      treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients must have a histologically confirmed diagnosis of squamous cell carcinoma,\n             operable or inoperable tumors, stage III (T3N0-1) and IVA-B (T1-4 N2-3M0 or T4N0-1M0)\n             of oral cavity, oropharynx, hypopharynx and larynx. For patients with oropharynx\n             primary, either HPV negative or HPV positive with a > 10 pack year tobacco history or\n             current smokers are eligible. HPV status should be determined before the enrollment\n             in only non-smokers with oropharynx primary by HPV in-situ hybridization and/or p16\n             immunostain.\n\n          2. Patients must have measurable disease of primary, nodes or both by clinical and\n             radiographic methods per RECIST v1.1..\n\n          3. No prior therapy, including surgery with curative intent, chemotherapy, radiation\n             therapy, immunotherapy, EGFR targeted therapies, or any other investigational agents.\n\n          4. Age >= 18 years.\n\n          5. ECOG performance status 0-1.\n\n          6. Patients must have normal hepatic, renal and bone marrow function.\n\n               -  Absolute neutrophil count >=1,000/ mm3 Count\n\n               -  Platelets >= 100,000/mm3 Count\n\n               -  Total serum bilirubin =< 1.5mg/dL Level:\n\n               -  AST and ALT =< 2.5 X ULN\n\n               -  Alkaline Phosphatase =< 2.5 X ULN\n\n               -  Total calculated creatinine clearance >= 60 mL/min\n\n          7. Patients with a history of a curatively treated malignancy must be disease-free for\n             at least two years except for carcinoma in situ of cervix and/or non-melanomatous\n             skin cancer.\n\n          8. Patients with the following within the last 6 months prior to pre-registration must\n             be evaluated by a cardiologist and/or neurologist prior to entry into the study.\n\n               -  Congestive heart failure > NYHA Class II\n\n               -  CVA/TIA\n\n               -  Unstable angina\n\n               -  Myocardial infarction (with or without ST elevation)\n\n          9. Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          1. Any prior radiation above the clavicles.\n\n          2. Any prior invasive malignancy (unless non-melanomatous resectable skin or the DFS is\n             2 years or more).\n\n          3. History of allergic reactions attributed to compounds of similar chemical or\n             biological composition to afatinib, or other agents used in study.\n\n          4. Cardiac left ventricular dysfunction with resting ejection fraction of less than\n             institutional lower limit of normal ( if no lower limit of normal is defined in the\n             institution, the lower limit is 50%)\n\n          5. Gastrointestinal tract disease resulting in an inability to take or absorb oral or\n             enteral medication.\n\n          6. Baseline significant gastrointestinal symptoms with diarrhoea as a major symptom or a\n             CTCAE Grade >1 diarrhoea of any etiology.\n\n          7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements.\n\n          8. Women of childbearing potential and sexually active males are strongly advised to use\n             an accepted and effective method of contraception.\n\n          9. Known pre-existing interstitial lung disease (ILD)\n\n         10. Pregnant women are excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "71", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732640", 
            "org_study_id": "J1266", 
            "secondary_id": "NA_00074085"
        }, 
        "intervention": [
            {
                "arm_group_label": "Study Arm", 
                "description": "Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.", 
                "intervention_name": "Afatinib", 
                "intervention_type": "Drug", 
                "other_name": "N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide"
            }, 
            {
                "arm_group_label": "Study Arm", 
                "description": "Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "TaxolR", 
                    "NSC 673089"
                ]
            }, 
            {
                "arm_group_label": "Study Arm", 
                "description": "Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": "cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)"
            }, 
            {
                "arm_group_label": "Study Arm", 
                "description": "Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cis-diaminedichloroplatinum Cis-diaminedichloroplatinum (II)", 
                    "diaminedichloroplatinum", 
                    "cis-platinum", 
                    "platinum", 
                    "Platinol", 
                    "Platinol-AQ", 
                    "DDP", 
                    "CDDP", 
                    "DACP", 
                    "NSC 119875 R R"
                ]
            }, 
            {
                "arm_group_label": "Study Arm", 
                "description": "Standard Fractionation 70 Gy /35 fractions at 2 Gy/day for 5 days per week.", 
                "intervention_name": "Intensity Modulated Radiation Therapy", 
                "intervention_type": "Radiation", 
                "other_name": "IMRT"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Squamous cell carcinoma of the head and neck", 
        "lastchanged_date": "March 23, 2014", 
        "location": [
            {
                "contact": {
                    "email": "cchung11@jhmi.edu", 
                    "last_name": "Christine Chung, MD", 
                    "phone": "410-502-0678"
                }, 
                "contact_backup": {
                    "email": "tsottna@jhmi.edu", 
                    "last_name": "Nancy Tsottles, RN", 
                    "phone": "410-614-5483"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins Sidney Kimmel Comprehensive Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jill.gilbert@vanderbilt.edu", 
                    "last_name": "Jill Gilbert, MD", 
                    "phone": "615-322-5000"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt Ingram Cancer Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed By Standard Chemoradiation In HPV-Negative or High-risk HPV-Positive Locally Advanced Stage III/IVa/IVb HNSCC", 
        "overall_contact": {
            "email": "cchung11@jhmi.edu", 
            "last_name": "Christine Chung, MD", 
            "phone": "410-502-0678"
        }, 
        "overall_contact_backup": {
            "email": "tsottna@jhmi.edu", 
            "last_name": "Nancy Tsottles, RN", 
            "phone": "410-614-5483"
        }, 
        "overall_official": {
            "affiliation": "Sidney Kimmel Comprehensive Cancer Center", 
            "last_name": "Christine Chung, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "United States: Data and Safety Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Phase I Objective:  To determine the MTD or recommended Phase II dose of oral afatinib in a combination with carboplatin AUC 6 and paclitaxel 175mg/m2 q 21 days as an induction regimen in patients with AJCC stage III and IVA-B HPV(-) HNSCC of oral cavity, oropharynx, hypopharynx and larynx.", 
                "measure": "Maximum Tolerated Dose (MTD)", 
                "safety_issue": "Yes", 
                "time_frame": "1 Year (Average)"
            }, 
            {
                "description": "Phase II Objective:  To estimate the objective tumor response rate to induction chemotherapy and toxicity in patients treated on the dose of afatinib determined as safe in phase I.", 
                "measure": "Objective Tumor Response", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732640"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To estimate the overall response rate after completion of chemoradiation.", 
                "measure": "Overall Response after Chemoradiation", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }, 
            {
                "description": "To estimate the 2 year progression free survival.", 
                "measure": "2 Year Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }, 
            {
                "description": "To estimate the median overall survival.", 
                "measure": "Median Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }, 
            {
                "description": "To estimate the biological marker activity of afatinib by serial sampling of tumor and blood samples from patients, and correlate with clinical and pathological response and outcomes. On- and off-target effects of afatinib will be assessed for the biological marker activity.", 
                "measure": "Biological Marker Activity of Afatinib", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }, 
            {
                "description": "To estimate the activity of afatinib by obtaining serial FLT-PET/CT and DW-MRI, And compare to standard of care CT images (which will be acquired at baseline and at the completion of treatment, and categorized per RECIST criteria) and correlated with response.", 
                "measure": "Activity of Afatinib Based on Serial FLT-PET/CT and DW-MRI", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }, 
            {
                "description": "To correlate the response with standard imaging CT/MRI and FDG PET pre and post treatment.", 
                "measure": "Correlate Standard Imaging Pre and Post Treatment", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }
        ], 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Vanderbilt-Ingram Cancer Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Comprehensive Cancer Network", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}